From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region

From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region

Background: Current guidelines recommend that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with proven cardiovascular benefit should be considered for first-line therapy in patients with type 2 diabetes (T2D) who have/are at high risk of atherosclerotic cardiovascular disease (CVD). Summary...

Full description

Bibliographic Details
Main Authors: Talal Ashour, Sami Azar, Akram Echtay, Muhammad Farooqi, Tarek Fiad, Mohamed Hassanein, Ahmed Hassoun, Abdul Jabbar, Amin Jayyousi, Kari Ranta, Hani Sabbour, Fatih Tangi, Ibrahim Turfanda
Format: Article
Language:English
Published: Karger Publishers 2023-11-01
Series:Dubai Diabetes and Endocrinology Journal
Subjects:
cardiovascular outcomes trials
cardiovascular risk
dulaglutide
glucagon-like peptide-1 receptor agonists
gulf and levant
primary prevention
rewind
Online Access:https://beta.karger.com/Article/FullText/534713

Similar Items

Similar Items